Bavarian Nordic A/S (OTCMKTS:BVNRY) Sees Significant Increase in Short Interest

Bavarian Nordic A/S (OTCMKTS:BVNRY - Get Free Report) was the target of a significant increase in short interest in the month of February. As of February 15th, there was short interest totalling 5,300 shares, an increase of 55.9% from the January 31st total of 3,400 shares. Based on an average daily volume of 24,500 shares, the days-to-cover ratio is presently 0.2 days.

Bavarian Nordic A/S Stock Performance

Shares of BVNRY stock traded up $0.36 during trading on Wednesday, hitting $8.04. 32,383 shares of the company were exchanged, compared to its average volume of 11,217. The firm has a market capitalization of $1.90 billion, a price-to-earnings ratio of 11.65 and a beta of 1.68. The business's 50-day simple moving average is $8.55 and its 200 day simple moving average is $9.91. Bavarian Nordic A/S has a twelve month low of $6.86 and a twelve month high of $14.60.

Bavarian Nordic A/S (OTCMKTS:BVNRY - Get Free Report) last posted its earnings results on Wednesday, March 5th. The company reported $0.47 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.40 by $0.07. Bavarian Nordic A/S had a net margin of 18.33% and a return on equity of 10.65%. On average, equities analysts forecast that Bavarian Nordic A/S will post 0.67 earnings per share for the current fiscal year.

Bavarian Nordic A/S Company Profile

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name.